Q-PAN H5N8/AS03 / GSK - LARVOL DELTA

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P1/2 | N=518 | Completed | Sponsor: GlaxoSmithKline | Trial completion date: May 2024 ➔ Sep 2024

Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P1/2 | N=518 | Completed | Sponsor: GlaxoSmithKline | Trial primary completion date: Dec 2023 ➔ May 2024

Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P1/2 | N=518 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P1/2 | N=518 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: GlaxoSmithKline | Phase classification: P2 ➔ P1/2

Phase classification • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P2 | N=520 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting | Phase classification: P1/2 ➔ P2

Enrollment open • Phase classification • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (clinicaltrials.gov) - P1/2 | N=520 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases